Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 3Breast Neoplasms 2Solid Tumours 1Side-effect of Antibiotic 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Long QT Syndrome 1Hot Flashes 1Hodgkin Disease 1Carcinoma, Renal Cell 1Bacteremia 1Advanced Breast Cancer 1

Interventions

AZD 6244 5GSK 1363089 3pazopanib 1ispinesib 1Topotecan 1SLC-0111 1Rifampin 1Omeprazole 1Moxifloxacin 1Midazolam 1Itraconazole 1Granisetron 1Fluconazole 1Famotidine 1Cytochrome P-450 CYP3A 1Cytochrome P-450 CYP2C19 1Cytochrome P-450 CYP1A2 1Carboplatin 1Carbon-14 1Caffeine 1BGC945 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumours × Moxifloxacin × Clear all
NCT02056392 2015-11-09

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

AstraZeneca

Phase 1 Completed
54 enrolled 31 charts
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡